Acumen Pharmaceuticals, Inc. (ABOS) Valuation — DCF, Graham & Comparables

Acumen Pharmaceuticals, Inc. (ABOS) — Price $2.61 HealthcareBiotechnology — NASDAQ

Latest reported results:

Valuation dashboard for Acumen Pharmaceuticals, Inc. (ABOS) with P/E N/A, P/B 3.39, EV/EBITDA -2.01 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.

Analysis Summary

Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.

At the current price of $2.61, ABOS has negative trailing earnings (P/E not meaningful) and an ROE of -136.27%. Market capitalisation stands at $189M.

Balance sheet quality for ABOS: current ratio of 4.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Valuation Ratios

Price / Book3.39
EV / EBITDA-2.01
Dividend Yield0.00%

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
ABOSAcumen Pharmaceuticals, Inc.$189M3.39-136.3%
0QZU.LVertex Pharmaceuticals Incorporated$131.8B
VRTXVertex Pharmaceuticals Incorporated$130.3B29.686.4523.3%
0R2M.LRegeneron Pharmaceuticals, Inc.$84.0B
REGNRegeneron Pharmaceuticals, Inc.$79.8B18.792.5713.8%
ARGXargenx SE$61.2B36.307.4021.7%
MRNAModerna, Inc.$57.8B1.34-39.2%
RVMDRevolution Medicines, Inc.$41.7B15.96-96.4%

Price

Price$2.61
Market Cap$189M
ExchangeNASDAQ
CountryUS

Profitability

Return on Equity-136.27%
Return on Invested Capital-118.57%
Return on Assets-90.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: ACTU · AGEN · ALEC · FATE · INO · IRD · MCRB

Explore sector: Healthcare · Biotechnology

More sections of ABOS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks